CERo Therapeutics Holdings, Inc. has announced significant findings from its Phase 1 clinical trial, known as CERTAIN-T, during a presentation at the Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The meeting is taking place in Salt Lake City, Utah, from February 4 to 6, 2026.
The data presented highlight the early results from the trial, showcasing the safety and tolerability of the company’s lead compound, CER-1236. This innovative cellular immunotherapy aims to target new pathways and mechanisms in the treatment of hematological malignancies. The interim results reflect a positive safety profile, with participants experiencing a rapid in vivo cell expansion. Specifically, the trial noted an impressive 20–70-fold expansion of cells, which peaked between days 7 and 14 after treatment, followed by sustained persistence.
Among the noteworthy outcomes is the case of an index patient diagnosed with acute myeloid leukemia (AML) that developed from myelodysplastic syndrome (MDS). This patient received a total of four infusions of CER-1236 over a five-month period, starting at the lowest dose level. Prior to treatment, the patient frequently required platelet transfusions. Remarkably, following the administration of CER-1236, the patient achieved transfusion independence that lasted over two months, surpassing the commonly accepted durability benchmark of 56 days.
The presentation at the ASTCT and CIBMTR meeting underscores CERo’s commitment to advancing novel therapies in the field of cellular immunotherapy. These findings not only contribute to the body of evidence supporting the potential efficacy of CER-1236 but also offer hope for patients grappling with challenging hematological conditions.
As CERo Therapeutics continues its clinical journey, the company remains focused on developing innovative solutions that could reshape treatment paradigms for patients facing serious blood disorders. Further updates on the CERTAIN-T trial and its outcomes are anticipated as the study progresses, promising to shed more light on the potential impact of CER-1236 in the field.
